Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2300 participants.

Also called NCT05380063

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05380063
Other papers using this trial's data
  • Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial BMJ (Clinical research ed.), 2026-05-12 DOI, PubMed 42120081, PMC13162091 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05380063. Randomized; quadruple masking; primary purpose treatment. Start 2023-02-14 (actual); primary completion 2025-07-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting
Acronym
TOP-CABG
Condition
Dual Antiplatelet Therapy
Condition
Bleeding
Condition
Myocardial Ischemia
Condition
Angina Pectoris
Intervention (Drug)
De-escalated Dual Antiplatelet Therapy
Intervention (Drug)
Dual Antiplatelet Therapy
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct05380063
Content hash
0ba01d0f53465f01080fe724d161bd47bd56b3e968c46fe75c05490308908ecc